Bio News

Takeda has secured FDA approval for Ojjaara, a narcolepsy drug expected to generate up to $3 billion in sales, or approximately 4.266 trillion won. Unlike existing symptom-relief treatments, Takeda says Ojjaara addresses the underlying cause of narcolepsy: orexin deficiency. The company plans to launch the product within 90 days after review by the U.S. Drug Enforcement Administration (DEA).

BIOBOOK TEAM
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%